Terms: = Lymphoma AND ERG, P11308, 2078 AND Treatment
51 results:
1. Transcriptome Analysis in Mexican Adults with Acute Lymphoblastic Leukemia.
Cruz-Miranda GM; Olarte-Carrillo I; Bárcenas-López DA; Martínez-Tovar A; Ramírez-Bello J; Ramos-Peñafiel CO; García-Laguna AI; Cerón-Maldonado R; May-Hau D; Jiménez-Morales S
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339034
[TBL] [Abstract] [Full Text] [Related]
2. Clinical Characteristics and Survival Analysis of Patients With Second Primary Malignancies After Hepatocellular Carcinoma Liver Transplantation: A SEER-based Analysis.
Ding Q; Wang K; Li Y; Peng P; Zhang D; Chang D; Wang W; Ren L; Tang F; Li Z
Am J Clin Oncol; 2023 Jul; 46(7):284-292. PubMed ID: 37145881
[TBL] [Abstract] [Full Text] [Related]
3. Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial.
Schwab C; Cranston RE; Ryan SL; Butler E; Winterman E; Hawking Z; Bashton M; Enshaei A; Russell LJ; Kingsbury Z; Peden JF; Barretta E; Murray J; Gibson J; Hinchliffe AC; Bain R; Vora A; Bentley DR; Ross MT; Moorman AV; Harrison CJ
Leukemia; 2023 Mar; 37(3):529-538. PubMed ID: 36550215
[TBL] [Abstract] [Full Text] [Related]
4. The kinetics of blast clearance are associated with copy number alterations in childhood B-cell acute lymphoblastic leukemia.
Urbańska Z; Lejman M; Taha J; Madzio J; Ostrowska K; Miarka-Walczyk K; Wypyszczak K; Styka B; Jakubowska J; Sędek Ł; Szczepański T; Stańczak M; Fendler W; Młynarski W; Pastorczak A
Neoplasia; 2023 Jan; 35():100840. PubMed ID: 36288679
[TBL] [Abstract] [Full Text] [Related]
5. Targeted treatment and Immunotherapy in High-risk and Relapsed/ Refractory Pediatric Acute Lymphoblastic Leukemia.
Graiqevci-Uka V; Behluli E; Spahiu L; Liehr T; Temaj G
Curr Pediatr Rev; 2023; 19(2):150-156. PubMed ID: 36056858
[TBL] [Abstract] [Full Text] [Related]
6. PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120.
Fazio G; Bresolin S; Silvestri D; Quadri M; Saitta C; Vendramini E; Buldini B; Palmi C; Bardini M; Grioni A; Rigamonti S; Galbiati M; Mecca S; Savino AM; Peloso A; Tu JW; Bhatia S; Borkhardt A; Micalizzi C; Lo Nigro L; Locatelli F; Conter V; Rizzari C; Valsecchi MG; Te Kronnie G; Biondi A; Cazzaniga G
EBioMedicine; 2022 Sep; 83():104224. PubMed ID: 35985167
[TBL] [Abstract] [Full Text] [Related]
7. Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials.
Creasey T; Barretta E; Ryan SL; Butler E; Kirkwood AA; Leongamornlert D; Papaemmanuil E; Patrick P; Clifton-Hadley L; Patel B; Menne T; McMillan AK; Harrison CJ; Rowntree CJ; Morley N; Marks DI; Fielding AK; Moorman AV
Haematologica; 2022 Sep; 107(9):2051-2063. PubMed ID: 34788984
[TBL] [Abstract] [Full Text] [Related]
8. Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification.
Schwab CJ; Murdy D; Butler E; Enshaei A; Winterman E; Cranston RE; Ryan S; Barretta E; Hawking Z; Murray J; Antony G; Vora A; Moorman AV; Harrison CJ
Br J Haematol; 2022 Feb; 196(3):753-763. PubMed ID: 34676543
[TBL] [Abstract] [Full Text] [Related]
9. Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Grimm SE; Witlox W; Wolff R; Chalker A; Hiligsmann M; Wijnen B; Ahmadu C; Ryder S; Armstrong N; Duffy S; Syndikus I; Kleijnen J; Joore MA
Pharmacoeconomics; 2022 May; 40(5):509-518. PubMed ID: 34664200
[TBL] [Abstract] [Full Text] [Related]
10. Proposal and clinical application of molecular genetic risk scoring system, "MRplus", for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre.
Gupta SK; Bakhshi S; Kamal VK; Gupta R; Sharma P; Pushpam D; Sahoo RK; Sharma A
Leuk Res; 2021 Dec; 111():106683. PubMed ID: 34371436
[TBL] [Abstract] [Full Text] [Related]
11. Lenalidomide with Rituximab for Previously Treated Follicular lymphoma and Marginal Zone lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Witlox WJA; Grimm SE; Riemsma R; Armstrong N; Ryder S; Duffy S; Carrera VH; Posadzki P; Worthy G; Pouwels XGLV; Ramaekers BLT; Kleijnen J; Joore MA; van Asselt ADI
Pharmacoeconomics; 2021 Feb; 39(2):171-180. PubMed ID: 33145711
[TBL] [Abstract] [Full Text] [Related]
12. Outcomes of Jehovah's Witnesses with hematological malignancies treated without transfusions - single center experience.
Drozd-Sokołowska JE; Waszczuk-Gajda A; Dwilewicz-Trojaczek J; Walesiak A; Krzyżanowska M; Paluszewska M; Wieczorek J; Jędrzejczak WW
Folia Med Cracov; 2020; 60(4):53-64. PubMed ID: 33821851
[TBL] [Abstract] [Full Text] [Related]
13. Tisagenlecleucel for the treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Walton M; Sharif S; Simmonds M; Claxton L; Hodgson R
Pharmacoeconomics; 2019 Oct; 37(10):1209-1217. PubMed ID: 30982165
[TBL] [Abstract] [Full Text] [Related]
14. Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Grimm SE; Fayter D; Ramaekers BLT; Petersohn S; Riemsma R; Armstrong N; Pouwels X; Witlox W; Noake C; Worthy G; Kleijnen J; Joore MA
Pharmacoeconomics; 2019 Oct; 37(10):1195-1207. PubMed ID: 30895564
[TBL] [Abstract] [Full Text] [Related]
15. The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Cox E; Wade R; Peron M; Dietz KC; Eastwood A; Palmer S; Griffin S
Pharmacoeconomics; 2019 Sep; 37(9):1081-1091. PubMed ID: 30887470
[TBL] [Abstract] [Full Text] [Related]
16. Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types.
van de Stolpe A; Holtzer L; van Ooijen H; Inda MA; Verhaegh W
Sci Rep; 2019 Feb; 9(1):1603. PubMed ID: 30733525
[TBL] [Abstract] [Full Text] [Related]
17. Obinutuzumab in Combination with Chemotherapy for the First-Line treatment of Patients with Advanced Follicular lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
Thielen FW; Büyükkaramikli NC; Riemsma R; Fayter D; Armstrong N; Wei CY; Huertas Carrera V; Misso K; Worthy G; Kleijnen J; Corro Ramos I
Pharmacoeconomics; 2019 Aug; 37(8):975-984. PubMed ID: 30547368
[TBL] [Abstract] [Full Text] [Related]
18. [Primary immunodeficiencies and haemato-oncology].
Müller J; Kovács G
Orv Hetil; 2018 Dec; 159(49):2073-2078. PubMed ID: 30525881
[TBL] [Abstract] [Full Text] [Related]
19. [Strategy for treatment of acute lymphoblastic leukemia].
Kobayashi Y
Rinsho Ketsueki; 2018; 59(10):2019-2027. PubMed ID: 30305504
[TBL] [Abstract] [Full Text] [Related]
20. Ceritinib for Untreated Anaplastic lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Claxton L; O'Connor J; Woolacott N; Wright K; Hodgson R
Pharmacoeconomics; 2019 May; 37(5):645-654. PubMed ID: 30298279
[TBL] [Abstract] [Full Text] [Related]
[Next]
